Genital Diseases, Female  >>  alisertib (MLN8237)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
alisertib (MLN8237) / Puma
NCT01091428 / 2009-011428-79: Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark P1data - ASCO
Jun 2012 - Jun 2012: P1data - ASCO
Completed
2
191
US
Alisertib, MLN8237, Paclitaxel
Millennium Pharmaceuticals, Inc.
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
08/14
07/17

Download Options